Phase II trial shows drug combination promising in advanced melanoma
the ONA take:
Clinical trial shows simultaneous administration of ipilimumab and nivolumab produced better treatment response in patients with advanced melanoma who had received no prior treatment.
The phase II, double-blind trial enrolled 142 patients with advanced melanoma who had not received prior treatments. The patients were randomly assigned to receive ipilimumab plus nivolumab followed by nivolumab alone or ipilimumab plus placebo followed by placebo alone.
The ipilimumab-nivolumab combination produced an overall response rate of 60% in the 109 patients without BRAF mutations, including 17% complete response and 43% partial response rates.
The ipilimumab-placebo combination resulted in overall response rate of 11%, with no complete responses and 11% partial response rate.
Among the 33 patients with BRAF V600 mutations, overall response rate was 44%, including 17% complete response and 26% partial response rates.
Ipilimumab and nivolumab produced better treatment response in patients with advanced melanoma who had received no prior treatment.
Sign Up for Free e-newsletters
- Avoiding the ED: Planned Strategies for Unplanned Urgent Cancer Care
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Art as Palliative Care: Bedside Intervention Improves Pain, Anxiety, Mood in Hospitalized Cancer Patients
- Unprotected Sex After Chemotherapy
- Mindfulness Training May Improve End-of-Life Conversations in Advanced Cancer
- Study Suggests Greater Focus on the Needs of Family Caregivers of Patients With Cancer
- First Antibody-Based Treatment Regimen Approved for First-Line Treatment of Multiple Myeloma
- Increased Diabetes Risk Associated With Cancer Development
- Childhood Neuroblastoma Survivors at Risk for Psych Impairment
- Drug Classification of Trastuzumab
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|